164 related articles for article (PubMed ID: 20649633)
1. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.
Rabøl R; Boushel R; Almdal T; Hansen CN; Ploug T; Haugaard SB; Prats C; Madsbad S; Dela F
Diabetes Obes Metab; 2010 Sep; 12(9):806-14. PubMed ID: 20649633
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.
Bajpeyi S; Pasarica M; Conley KE; Newcomer BR; Jubrias SA; Gamboa C; Murray K; Sereda O; Sparks LM; Smith SR
Metabolism; 2017 Apr; 69():24-32. PubMed ID: 28285649
[TBL] [Abstract][Full Text] [Related]
3. Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.
Schrauwen P; Mensink M; Schaart G; Moonen-Kornips E; Sels JP; Blaak EE; Russell AP; Hesselink MK
J Clin Endocrinol Metab; 2006 Apr; 91(4):1520-5. PubMed ID: 16384852
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes.
Fiorentino TV; Monroy A; Kamath S; Sotero R; Cas MD; Daniele G; Chavez AO; Abdul-Ghani M; Hribal ML; Sesti G; Tripathy D; DeFronzo RA; Folli F
Metabolism; 2021 Jan; 114():154416. PubMed ID: 33137378
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Deeg MA; Buse JB; Goldberg RB; Kendall DM; Zagar AJ; Jacober SJ; Khan MA; Perez AT; Tan MH;
Diabetes Care; 2007 Oct; 30(10):2458-64. PubMed ID: 17595355
[TBL] [Abstract][Full Text] [Related]
6. Effect of hyperglycemia on mitochondrial respiration in type 2 diabetes.
Rabøl R; Højberg PM; Almdal T; Boushel R; Haugaard SB; Madsbad S; Dela F
J Clin Endocrinol Metab; 2009 Apr; 94(4):1372-8. PubMed ID: 19141588
[TBL] [Abstract][Full Text] [Related]
7. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
[TBL] [Abstract][Full Text] [Related]
8. Improved glycaemic control decreases inner mitochondrial membrane leak in type 2 diabetes.
Rabøl R; Højberg PM; Almdal T; Boushel R; Haugaard SB; Madsbad S; Dela F
Diabetes Obes Metab; 2009 Apr; 11(4):355-60. PubMed ID: 19267714
[TBL] [Abstract][Full Text] [Related]
9. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Khan MA; St Peter JV; Xue JL
Diabetes Care; 2002 Apr; 25(4):708-11. PubMed ID: 11919129
[TBL] [Abstract][Full Text] [Related]
11. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
12. A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus.
Pagel-Langenickel I; Schwartz DR; Arena RA; Minerbi DC; Johnson DT; Waclawiw MA; Cannon RO; Balaban RS; Tripodi DJ; Sack MN
Am J Physiol Heart Circ Physiol; 2007 Nov; 293(5):H2659-66. PubMed ID: 17890427
[TBL] [Abstract][Full Text] [Related]
13. Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.
Djaouti L; Jourdan T; Demizieux L; Chevrot M; Gresti J; Vergès B; Degrace P
Diabetes Metab Res Rev; 2010 May; 26(4):297-305. PubMed ID: 20503262
[TBL] [Abstract][Full Text] [Related]
14. Reduced skeletal muscle mitochondrial respiration and improved glucose metabolism in nondiabetic obese women during a very low calorie dietary intervention leading to rapid weight loss.
Rabøl R; Svendsen PF; Skovbro M; Boushel R; Haugaard SB; Schjerling P; Schrauwen P; Hesselink MK; Nilas L; Madsbad S; Dela F
Metabolism; 2009 Aug; 58(8):1145-52. PubMed ID: 19454354
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.
Takada S; Hirabayashi K; Kinugawa S; Yokota T; Matsushima S; Suga T; Kadoguchi T; Fukushima A; Homma T; Mizushima W; Masaki Y; Furihata T; Katsuyama R; Okita K; Tsutsui H
Eur J Pharmacol; 2014 Oct; 740():690-6. PubMed ID: 24964389
[TBL] [Abstract][Full Text] [Related]
16. Long-term rates of mitochondrial protein synthesis are increased in mouse skeletal muscle with high-fat feeding regardless of insulin-sensitizing treatment.
Newsom SA; Miller BF; Hamilton KL; Ehrlicher SE; Stierwalt HD; Robinson MM
Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E552-E562. PubMed ID: 28698283
[TBL] [Abstract][Full Text] [Related]
17. Regional anatomic differences in skeletal muscle mitochondrial respiration in type 2 diabetes and obesity.
Rabøl R; Larsen S; Højberg PM; Almdal T; Boushel R; Haugaard SB; Andersen JL; Madsbad S; Dela F
J Clin Endocrinol Metab; 2010 Feb; 95(2):857-63. PubMed ID: 20061415
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
[TBL] [Abstract][Full Text] [Related]
20. The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function.
Schrauwen-Hinderling VB; Mensink M; Hesselink MK; Sels JP; Kooi ME; Schrauwen P
J Clin Endocrinol Metab; 2008 Jul; 93(7):2917-21. PubMed ID: 18460571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
